LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug clas… Read more
LIMITED OFFER
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases.
A brief history of each drug’s development and submission is provided, along with a more detailed analysis of the mechanism(s) of action involved in therapeutic activity or related to the insurgence of specific adverse events. Early chapters focus on general characteristics of TKIs, typology, and classification of adverse events, while the final chapters analyze TKIs as AE inducers and classes of AEs by system or organ involvement.
This comprehensive resource compiles and critically reviews all of the relevant safety data for this class of drugs, with the goal of improving the understanding of pathogenesis and facilitating the prevention, monitoring, and management of these adverse events.
Intended for pharmacologists, clinicians and specialists including oncologists, drug safety control officials and drug developers and producers who are working to find effective molecules with the lowest adverse effects profiles; academics involved in drug safety issues and public health professionals
Part I: General Aspects
1. Introduction2. Protein and Lipid Kinases3. Kinase Inhibitors4. Adverse Events
Part II: Oncotargeted Kinase Inhibitors
5. Imatinib6. Gefitinib7. Erlotinib8. Sorafenib9. Sunitinib10. Dasatinib11. Lapatinib12. Nilotinib13. Pazopanib14. Vandetanib15. Vemurafenib16. Crizotinib17. Ruxolitinib18. Axitinib19. Bosutinib20. Regorafenib21. Cabozantinib22. Ponatinib23. Dabrafenib24. Trametinib25. Adatinib26. Idelalisib27. Ibrutinib
Part III: Overview
28. Kinase Inhibitors as Adverse Event Inducers29. Kinase Inhibitors as Drug Class Events30. Conclusion and Perspectives
GT
School of Medicine and Surgery
Coordinator of the Teachers’ Committee for the Master in Translational Biomedicine
Universita degli Studi di Verona, Italy